

**Supplemental Table 2. Potential areas for intervention in infectious diseases that affect the nervous system, with references**

Disease	Vaccine available	Control of Zoonotic Reservoirs	Control of Vector populations	Treatment
<b>VIRAL</b>				
Dengue	New dengue vaccines being tested in large field trials <sup>1</sup>	NA	Yes	None available
Chikungunya	No	NA	Yes	None available
Japanese B encephalitis	Yes	No	Yes	None available
Rabies	Yes	Yes	NA	None available
HSV encephalitis	No	NA	NA	Yes
VZV	Yes	NA	NA	Yes
Congenital CMV	No	NA	NA	Yes
<b>HIV-RELATED</b>				
HIV	No	NA	NA	Yes
Cryptococcal meningitis	No	NA	NA	Yes
Toxoplasma	No	Yes	NA	Yes
<b>BACTERIAL</b>				
Neonatal sepsis and meningitis	No	NA	NA	Yes
Bacterial meningitis	Yes, for H. influenza type b, and pneumococcal (multiple serotypes) and meningococcal (A, C, Y, W-135) meningitis	NA	NA	Yes
Tuberculous meningitis	Partial protection provided by BCG vaccination <sup>2</sup>	Infrequent (cases due to <i>M. bovis</i> and <i>M. caprae</i> , which are present in cattle, reported) <sup>3</sup>	NA	Yes
Neurosyphilis				
<b>PARASITIC</b>				
Neurocysticercosis	No. Porcine vaccine being tested <sup>4</sup>	Yes	NA	Yes
Malaria	RTS,S vaccine had efficacy in phase 3 studies <sup>5</sup> ; other vaccines being developed	NA except for <i>P. knowlesi</i>	Yes	Yes
Soil-transmitted helminths	No. Hookworm vaccine in phase I trials but linked to adverse events <sup>6</sup>	NA for the primary soil-transmitted helminths	NA	Yes
Schistosomiasis	No. Phase I vaccine trials <sup>7</sup>	Bovine vaccine trials underway for <i>S. japonicum</i> <sup>8</sup>	Yes	Yes

Abbreviations: NA, not applicable

## REFERENCES

- 1 Villar, L. *et al.* Efficacy of a tetravalent dengue vaccine in children in Latin America. *N Engl J Med* **372**, 113-123, doi:10.1056/NEJMoa1411037 (2015).
- 2 Rodrigues, C. L. *et al.* Spectrum of cognitive impairment in neurocysticercosis: differences according to disease phase. *Neurology* **78**, 861-866, doi:10.1212/WNL.0b013e31824c46d1 (2012).
- 3 Hansen, N. *et al.* Human Tuberculous Meningitis Caused by *Mycobacterium caprae*. *Case reports in neurology* **4**, 54-60, doi:10.1159/000337299 (2012).
- 4 Lightowlers, M. W. Control of *Taenia solium* taeniasis/cysticercosis: past practices and new possibilities. *Parasitology* **140**, 1566-1577, doi:10.1017/S0031182013001005 (2013).
- 5 RTS, S. C. T. P. *et al.* A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. *N Engl J Med* **367**, 2284-2295, doi:10.1056/NEJMoa1208394 (2012).
- 6 Diemert, D. J. *et al.* Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. *The Journal of allergy and clinical immunology* **130**, 169-176 e166, doi:10.1016/j.jaci.2012.04.027 (2012).
- 7 Riveau, G. *et al.* Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. *PLoS neglected tropical diseases* **6**, e1704, doi:10.1371/journal.pntd.0001704 (2012).
- 8 Shi, F. *et al.* Field testing of *Schistosoma japonicum* DNA vaccines in cattle in China. *Vaccine* **20**, 3629-3631 (2002).